VBI Vaccines (NASDAQ:VBIV) and TapImmune (NASDAQ:TPIV) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership.
Earnings and Valuation
This table compares VBI Vaccines and TapImmune’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|VBI Vaccines||$3.36 million||57.26||-$63.60 million||($0.97)||-2.03|
Institutional & Insider Ownership
53.0% of VBI Vaccines shares are owned by institutional investors. Comparatively, 10.9% of TapImmune shares are owned by institutional investors. 16.2% of VBI Vaccines shares are owned by insiders. Comparatively, 3.3% of TapImmune shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This table compares VBI Vaccines and TapImmune’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent recommendations and price targets for VBI Vaccines and TapImmune, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
VBI Vaccines presently has a consensus target price of $10.50, suggesting a potential upside of 432.99%. TapImmune has a consensus target price of $5.00, suggesting a potential downside of 40.05%. Given VBI Vaccines’ higher possible upside, equities research analysts clearly believe VBI Vaccines is more favorable than TapImmune.
VBI Vaccines beats TapImmune on 5 of the 8 factors compared between the two stocks.
About VBI Vaccines
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus. It is also developing cytomegalovirus vaccine candidate for infectious disease; and glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts.
TapImmune, Inc., a clinical-stage immuno-oncology company, develops peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease. The company offers TPIV100/110 Peptide vaccine, which has completed phase I human clinical trials, used for the treatment of HER2/neu+ breast cancer; and TPIV200 Peptide vaccine, which is in Phase II clinical trial for the treatment of folate alpha/triple-negative breast and ovarian cancer. It also focuses on developing PolyStart, a DNA expression technology, which is in pre-clinical stage to enhance the function of killer T-cells (CD8+) and helper T-cells (CD4+) applied in prime and boost vaccine methodology. The company was incorporated in 1991 and is headquartered in Jacksonville, Florida.
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.